8-K: Vivani Medical Announces Positive Preclinical Data for NPM-139 Semaglutide Implant, Showing Potential for Once-Yearly Dosing

Vivani Medical's NPM-139 semaglutide implant demonstrated nearly 20% placebo-adjusted weight loss in preclinical studies, suggesting potential for convenient once or twice-yearly dosing for chronic weight management.

Summary

• Vivani Medical announced positive preclinical data for NPM-139, a subdermal semaglutide implant for chronic weight management.
• The implant uses NanoPortal technology to deliver semaglutide, the active ingredient in drugs like Ozempic and Wegovy.
• In preclinical studies, NPM-139 resulted in nearly 20% placebo-adjusted weight loss from a single administration in rats.
• The company anticipates that NPM-139 could be administered once or twice yearly.
• Vivani believes its NanoPortal implant technology can improve medication adherence and tolerability, potentially transforming GLP-1 therapy adoption.
• The company's first-in-human study with NPM-115, LIBERATE-1, is ongoing, with top-line data expected by mid-2025.
• LIBERATE-1 will provide critical information to support the development of NPM-139 and other pipeline programs.

Sentiment

Score: 7

Explanation: The announcement is positive due to the promising preclinical data and potential for improved drug delivery. However, it's still early-stage development, and risks remain.

Positives

• Positive preclinical data for NPM-139 suggests potential for effective weight management with less frequent dosing.
• NanoPortal technology could improve medication adherence and tolerability, addressing a key challenge in chronic disease management.
• The LIBERATE-1 study is progressing, with results expected in mid-2025, which will inform the development of NPM-139.
• The company has successfully utilized research and development rebates from the Australian government to defray a portion of the costs from the clinical trial.
• The company believes that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes.

Risks

• The forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control.
• Actual results and outcomes may differ materially from those indicated in the forward-looking statements.
• Risks related to the development and commercialization of Vivani's products, including NPM-115, NPM-139, and NPM-119.
• Potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities.
• Risks related to the initiation, enrollment and conduct of Vivani's planned clinical trials and the results therefrom.
• Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business.
• Market conditions and the ability of Cortigent to complete its intended spin-off from the Company.

Future Outlook

Vivani anticipates top-line data from the LIBERATE-1 study in mid-2025 and plans to use this data to support the development of NPM-139 and other pipeline programs. The company also anticipates being able to utilize similar rebates going forward from the Australian government for research and development expenses.

Management Comments

• Adam Mendelsohn, Ph.D., Vivani Medical's Chief Executive Officer, stated that the primary expected advantages of their proprietary NanoPortal implant technology, improving medication adherence and medication tolerability, have the potential to transform and expand the adoption of GLP-1 therapy in the future.

Industry Context

The announcement highlights Vivani's efforts to compete in the growing market for GLP-1 therapies, dominated by drugs like Ozempic and Wegovy. Vivani aims to differentiate itself through its NanoPortal implant technology, offering potentially improved adherence and convenience compared to existing injectable and oral options.

Comparison to Industry Standards

• Ozempic and Wegovy, both semaglutide-based drugs from Novo Nordisk, are leading treatments in the GLP-1 market.
• These drugs require weekly injections, while Vivani's NPM-139 aims for once or twice-yearly dosing.
• Bydureon BCise, an exenatide injection from AstraZeneca, is another GLP-1 therapy that requires weekly administration.
• Vivani's NPM-115, like Bydureon BCise, uses exenatide, but aims to provide a longer duration of action through its implant technology.
• The company believes that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.

Stakeholder Impact

• Shareholders may react positively to the promising preclinical data.
• Patients could benefit from a more convenient and effective weight management option.
• The company's employees are involved in the development and clinical trials of the new implant.
• Payers could benefit from improved medication adherence and reduced healthcare costs.

Next Steps

• Continue development of NPM-139 based on preclinical data and insights from the LIBERATE-1 study.
• Report top-line data from the LIBERATE-1 study in mid-2025.
• Advance the development of NPM-115 and NPM-119.
• Pursue regulatory submissions based on clinical data generated in Australia.

Key Dates

Keywords

semaglutide implant, NPM-139, weight management, NanoPortal, GLP-1, Vivani Medical, preclinical data, LIBERATE-1, NPM-115, chronic disease, obesity